vs
Side-by-side financial comparison of Baxter International (BAX) and Dole plc (DOLE). Click either name above to swap in a different company.
Baxter International is the larger business by last-quarter revenue ($3.0B vs $2.3B, roughly 1.3× Dole plc). Dole plc runs the higher net margin — 0.2% vs -37.9%, a 38.2% gap on every dollar of revenue. On growth, Baxter International posted the faster year-over-year revenue change (458.0% vs 10.5%). Over the past eight quarters, Dole plc's revenue compounded faster (3.2% CAGR vs -9.0%).
Baxter International Inc. is an American multinational healthcare company with headquarters in Deerfield, Illinois.
Dole plc is an Irish-American agricultural multinational corporation headquartered in Dublin, Ireland. The company is among the world's largest producers of fruit and vegetables, operating with 38,500 full-time and seasonal employees who supply some 300 products in 75 countries. Dole reported 2021 revenues of $6.5 billion.
BAX vs DOLE — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.0B | $2.3B |
| Net Profit | $-1.1B | $5.1M |
| Gross Margin | 19.4% | 6.8% |
| Operating Margin | -24.5% | 1.1% |
| Net Margin | -37.9% | 0.2% |
| Revenue YoY | 458.0% | 10.5% |
| Net Profit YoY | -120.3% | -64.6% |
| EPS (diluted) | $-2.21 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.0B | — | ||
| Q3 25 | $2.8B | $2.3B | ||
| Q2 25 | $2.8B | $2.4B | ||
| Q1 25 | $2.6B | $2.1B | ||
| Q4 24 | $533.0M | — | ||
| Q3 24 | $2.7B | $2.1B | ||
| Q2 24 | $3.8B | $2.1B | ||
| Q1 24 | $3.6B | $2.1B |
| Q4 25 | $-1.1B | — | ||
| Q3 25 | $-46.0M | $5.1M | ||
| Q2 25 | $91.0M | $10.0M | ||
| Q1 25 | $126.0M | $38.9M | ||
| Q4 24 | $-512.0M | — | ||
| Q3 24 | $140.0M | $14.4M | ||
| Q2 24 | $-314.0M | $80.1M | ||
| Q1 24 | $37.0M | $70.1M |
| Q4 25 | 19.4% | — | ||
| Q3 25 | 33.5% | 6.8% | ||
| Q2 25 | 35.3% | 9.0% | ||
| Q1 25 | 32.8% | 8.7% | ||
| Q4 24 | 25.0% | — | ||
| Q3 24 | 38.3% | 8.0% | ||
| Q2 24 | 37.5% | 9.4% | ||
| Q1 24 | 38.6% | 9.2% |
| Q4 25 | -24.5% | — | ||
| Q3 25 | 6.1% | 1.1% | ||
| Q2 25 | 6.8% | 4.3% | ||
| Q1 25 | 2.2% | 3.2% | ||
| Q4 24 | -25.5% | — | ||
| Q3 24 | 5.7% | 2.3% | ||
| Q2 24 | -5.0% | 4.0% | ||
| Q1 24 | 5.2% | 5.3% |
| Q4 25 | -37.9% | — | ||
| Q3 25 | -1.6% | 0.2% | ||
| Q2 25 | 3.2% | 0.4% | ||
| Q1 25 | 4.8% | 1.9% | ||
| Q4 24 | -96.1% | — | ||
| Q3 24 | 5.2% | 0.7% | ||
| Q2 24 | -8.2% | 3.8% | ||
| Q1 24 | 1.0% | 3.3% |
| Q4 25 | $-2.21 | — | ||
| Q3 25 | $-0.09 | $0.05 | ||
| Q2 25 | $0.18 | $0.10 | ||
| Q1 25 | $0.25 | $0.41 | ||
| Q4 24 | $-0.99 | — | ||
| Q3 24 | $0.27 | $0.15 | ||
| Q2 24 | $-0.62 | $0.84 | ||
| Q1 24 | $0.07 | $0.74 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.0B | $321.0M |
| Total DebtLower is stronger | $9.5B | — |
| Stockholders' EquityBook value | $6.1B | $1.4B |
| Total Assets | $20.1B | $4.5B |
| Debt / EquityLower = less leverage | 1.55× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.0B | — | ||
| Q3 25 | $1.7B | $321.0M | ||
| Q2 25 | $1.7B | $323.1M | ||
| Q1 25 | $2.3B | $261.0M | ||
| Q4 24 | $1.8B | — | ||
| Q3 24 | $1.4B | $266.4M | ||
| Q2 24 | $2.1B | $225.8M | ||
| Q1 24 | $3.0B | $245.5M |
| Q4 25 | $9.5B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $10.4B | — | ||
| Q3 24 | $10.4B | — | ||
| Q2 24 | $10.4B | — | ||
| Q1 24 | $11.1B | — |
| Q4 25 | $6.1B | — | ||
| Q3 25 | $7.2B | $1.4B | ||
| Q2 25 | $7.3B | $1.4B | ||
| Q1 25 | $7.1B | $1.3B | ||
| Q4 24 | $7.0B | — | ||
| Q3 24 | $7.9B | $1.4B | ||
| Q2 24 | $7.6B | $1.4B | ||
| Q1 24 | $8.2B | $1.3B |
| Q4 25 | $20.1B | — | ||
| Q3 25 | $21.1B | $4.5B | ||
| Q2 25 | $21.0B | $4.7B | ||
| Q1 25 | $21.3B | $4.5B | ||
| Q4 24 | $25.8B | — | ||
| Q3 24 | $26.7B | $4.5B | ||
| Q2 24 | $26.3B | $4.4B | ||
| Q1 24 | $27.8B | $4.5B |
| Q4 25 | 1.55× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.49× | — | ||
| Q3 24 | 1.33× | — | ||
| Q2 24 | 1.37× | — | ||
| Q1 24 | 1.36× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $584.0M | $87.4M |
| Free Cash FlowOCF − Capex | — | $66.5M |
| FCF MarginFCF / Revenue | — | 2.9% |
| Capex IntensityCapex / Revenue | — | 0.9% |
| Cash ConversionOCF / Net Profit | — | 17.12× |
| TTM Free Cash FlowTrailing 4 quarters | — | $13.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $584.0M | — | ||
| Q3 25 | $237.0M | $87.4M | ||
| Q2 25 | $217.0M | $18.3M | ||
| Q1 25 | $-193.0M | $-78.8M | ||
| Q4 24 | $488.0M | — | ||
| Q3 24 | $253.0M | $101.0M | ||
| Q2 24 | $115.0M | $40.2M | ||
| Q1 24 | $163.0M | $-35.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | $66.5M | ||
| Q2 25 | — | $-1.0M | ||
| Q1 25 | — | $-131.6M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $79.9M | ||
| Q2 24 | — | $22.8M | ||
| Q1 24 | — | $-53.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | 2.9% | ||
| Q2 25 | — | -0.0% | ||
| Q1 25 | — | -6.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.9% | ||
| Q2 24 | — | 1.1% | ||
| Q1 24 | — | -2.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.9% | ||
| Q2 25 | — | 0.8% | ||
| Q1 25 | — | 2.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.0% | ||
| Q2 24 | — | 0.8% | ||
| Q1 24 | — | 0.9% |
| Q4 25 | — | — | ||
| Q3 25 | — | 17.12× | ||
| Q2 25 | 2.38× | 1.84× | ||
| Q1 25 | -1.53× | -2.02× | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.81× | 7.01× | ||
| Q2 24 | — | 0.50× | ||
| Q1 24 | 4.41× | -0.50× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BAX
| Other | $1.5B | 51% |
| Infusion Therapies And Technologies | $543.0M | 18% |
| Pharmaceutical Compounding | $316.0M | 11% |
| Front Line Care | $219.0M | 7% |
| Injectables And Anesthesia | $190.0M | 6% |
| Advanced Surgery | $177.0M | 6% |
DOLE
Segment breakdown not available.
